2021
DOI: 10.1038/s41392-021-00645-w
|View full text |Cite
|
Sign up to set email alerts
|

Spatiotemporal control of CRISPR/Cas9 gene editing

Abstract: The clustered regularly interspaced short palindromic repeats (CRISPR)/associated protein 9 (CRISPR/Cas9) gene editing technology, as a revolutionary breakthrough in genetic engineering, offers a promising platform to improve the treatment of various genetic and infectious diseases because of its simple design and powerful ability to edit different loci simultaneously. However, failure to conduct precise gene editing in specific tissues or cells within a certain time may result in undesirable consequences, suc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
55
0
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1

Relationship

5
4

Authors

Journals

citations
Cited by 98 publications
(68 citation statements)
references
References 176 publications
0
55
0
1
Order By: Relevance
“…Second, by leveraging all known cis - and trans -regulatory sites, CRISPR-Cas9 can be repurposed for simultaneous, reversible gene activation or silencing by conjugating the catalytically inactive caspase9 dCas9 to an effector protein [ 276 , 277 , 278 ]. A short guide RNA (sgRNA) with a protospacer adjacent motif (PAM) complementary to the targeted genomic sites can then direct the dCas9-KRAB-Effector transcriptional suppresser [ 279 ] or the dCas9-SAM synergistic activation mediator [ 280 ], to specific genetic loci of interest.…”
Section: Tackling the Epigenetic Contribution To Ocular Diseases For ...mentioning
confidence: 99%
“…Second, by leveraging all known cis - and trans -regulatory sites, CRISPR-Cas9 can be repurposed for simultaneous, reversible gene activation or silencing by conjugating the catalytically inactive caspase9 dCas9 to an effector protein [ 276 , 277 , 278 ]. A short guide RNA (sgRNA) with a protospacer adjacent motif (PAM) complementary to the targeted genomic sites can then direct the dCas9-KRAB-Effector transcriptional suppresser [ 279 ] or the dCas9-SAM synergistic activation mediator [ 280 ], to specific genetic loci of interest.…”
Section: Tackling the Epigenetic Contribution To Ocular Diseases For ...mentioning
confidence: 99%
“…Taming Cas9 expression or activity using pharmacological approaches might therefore be a prospective route for temporally restricted or pulsed endogenous gene activation, possibly reducing expected immune responses upon constitutive Cas9 expression (159) and deserves a future validation in in vivo models. Bioengineering of Cas9 proteins as well as elaborate cell-type specific and temporally resolved Cas9 expression systems (151) are therefore essential ventures for safe and limited CRISPR/Cas9 based applications (71). Protein-based anti-CRISPRs, which are accessory proteins with fewer than 200 amino acids called "anti-CRISPRs, " can function as antagonists of CRISPR systems and achieve context-specific inhibition of Cas9.…”
Section: Controlling Cas9 Function and Side-effectsmentioning
confidence: 99%
“…A given stimulus to control spatial and temporal delivery has received lots of attention. [ 140 ] Stimuli‐responsive nanoparticles can facilitate endosome escape and liberate the CRISPR cargo with remote control. Moreover, designing ligands for ASGPR‐mediated hepatocyte targeting has been investigated most in the relative applications.…”
Section: Potential Crispr Therapeutics For Viral Hepatitis and Hepatocellular Carcinomamentioning
confidence: 99%